HPTN 083 Logo

Give PrEP a Shot (HPTN 083)

Assessing the safety and efficacy of cabotegravir, an investigational, long-acting, injectable HIV medication, versus Truvada, the only FDA-approved medication for HIV prevention. Participants are randomized 1:1 to receive active cabotegravir or Truvada and an appropriate matching placebo. During the first step of the study, participants take oral cabotegravir or oral Truvada for five weeks; in the second step, participants continue oral Truvada (or placebo) and begin receiving gluteal injections of cabotegravir (or placebo) every eight weeks for up to 3.5 years. In step three, all participants receive open-label Truvada for one year to prevent HIV infection while residual cabotegravir levels slowly dissipate over time.
Population: MSM, transgender women (born male)
Location: Chapel Hill / Greensboro
Duration: Up to 4.5 years
Contact: Becky Straub, RN, 919-843-9975 or Miriam Chicurel-Bayard, RN, 919-843-9922
WEB: Fill out our contact form for this and other prevention studies

HPTN 087

The HIV Vaccine Trials Network (HVTN), the HIV Prevention Trials Network (HPTN), and the University of North Carolina at Chapel Hill are doing a study to test the antibody against HIV called VRC07-523LS. HIV is the virus that causes AIDS. Antibodies are one of the ways the human body fights infection. Antibodies are natural proteins that the body can make to prevent infectious agents such as bacteria and viruses from making you sick. Researchers can also make antibodies in laboratories and give them to people intravenously (with an IV) or by injection. Participants will be randomized into 1 of 6 arms, receiving up to 5 IV infusions or injections. This is a multicenter, randomized phase 1 clinical trial and will last for 2 years.
Population: Healthy women & men, 18-50 years old
Locations: Chapel Hill
Duration: 2 years
Contact: Maureen Furlong, RN, 919-966-8524 or Becky Straub, RN, 919-843-9975